Lv4
600 积分 2025-10-29 加入
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
21小时前
待确认
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
6天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
6天前
已完结
Oesophageal cancer
7天前
已完结
Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review
9天前
已完结
Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities
9天前
已完结
Rare Case of Dual Paraneoplastic Endocrinopathies in Small Cell Lung Cancer: Triphasic Electrolyte Presentation
11天前
已关闭
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
14天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
15天前
已完结
PL02.12 Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with EGFR+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONi
15天前
已完结
皖公网安备34019202002308
